Results 201 to 210 of about 119,198,728 (316)

Metal nanostructure‐coupled label‐free localized surface plasmon resonance biosensors for rapid and sensitive disease diagnosis

open access: yesBMEMat, EarlyView.
LSPR biosensing enables rapid, sensitive, and low‐sample‐volume detection of biomarkers, with broad applications in diagnosing cancer, infectious, and chronic diseases. Advances in nanostructure design, micro/nanofabrication, and microfluidic integration have expanded the potential of LSPR sensors in biomedical diagnostics.
Zhaoxin Geng   +4 more
wiley   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

open access: yesBMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim   +9 more
wiley   +1 more source

EuroHePP: The European Toolkit to Strengthen National Responses for the Elimination of Viral Hepatitis in Prisons. [PDF]

open access: yesLiver Int
Fondelli S   +23 more
europepmc   +1 more source

Short‐Term Effects of Golden Rice Cookies Enriched With Piper crocatum Extract on Lipid Profiles in Adults With Diabetes: A Quasi‐Experimental Study

open access: yesChronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Background Diabetes mellitus (DM) commonly coexists with dyslipidemia and elevated cardiovascular risk. Food‐based interventions containing antioxidants and polyphenols may support lipid metabolism. This study evaluated the short‐term effects of Golden Rice cookies enriched with active Piper crocatum extract on lipid profiles in adults with DM.
Altje Suwardi Abram   +2 more
wiley   +1 more source

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann   +4 more
wiley   +1 more source

Hepatitis B: Are You At Risk? (Vietnamese)

open access: yes
Read the hepatitis B fact sheet in ...

core  

A Practical Guide to Implementing Real‐World Evidence as Primary Basis for Approval and Label Expansion

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
In June 2026, the FDA issued a revised draft guidance describing the circumstances in which one adequate and well‐controlled clinical investigation plus confirmatory evidence may satisfy the statutory substantial evidence standard for establishing efficacy and safety. Confirmatory evidence includes real‐world evidence (RWE).
Tracy J. Mayne   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy